期刊文献+

体外转染PTEN抑制胆管癌QBC939细胞生长及下调mTOR表达的研究 被引量:2

Investigation of the inhibition of the cell growth and down-regulation of mTOR in the cholangiocarcinoma QBC939 cells transfected with plasmid PTEN in vitro
下载PDF
导出
摘要 目的研究信号转导通路PI3K/AKT/PTEN/mTOR中抑癌基因PTEN在体外对胆管癌QBC 9 3 9细胞生长的抑制作用,及对下游mTOR表达的影响。方法用携带有野生型PTEN和突变型PTEN的真核表达载体及空载质粒转染QBC 9 3 9;用W estern blot检测转染后PTEN蛋白的表达及蛋白激酶B磷酸化的变化;流式细胞技术检测细胞周期和细胞凋亡情况,及对下游mTOR表达的影响。结果野生型PTEN转染成功后的QBC 9 3 9细胞中PTEN明显上升,磷酸化AKT明显下降,mTOR表达也明显下调;而突变型PTEN转染后的细胞中PTEN上升,但磷酸化AKT的变化不明显,mTOR的表达亦无明显变化。结论PTEN通过磷酸化AKT使之活化,进一步使下游的mTOR同步下调,继而调节肿瘤细胞周期和细胞凋亡。在PI3K/AKT/PTEN/mTOR信号转导途径中,PTEN与mTOR通过AKT的磷酸化有密切关系。 Objective To investigate the effects of the tumor suppressor gene PTEN in growing inhibition and down-regulating mTOR in cholangiocarcinoma QBC939 cells in vitro. Methods QBC939 cells were transfected with plasmids wild-type PTEN and C124S-PTEN in vitro. After transfection, the expression of the PTEN and phosphorylation of AKT and mTOR was detected by Western blot. Flow cytometry was used to analyze apoptosis and cell cycle of the transfected cells. Results Compared with the control, the expression of phosphorylation AKT was decreased and mTOR were down-regulated respectively when transfected with the wild-type PTEN. However, after transfection with mutation-type PTEN, the level of PTEN in the cells by increased, but phosphorylation AKT level and mTOR expression had no significant change. Conclusions PTEN can be actived by phosphorylated AKT. Actived AKT decreased the mTOR which led to tumor cells apoptosis and regulation of the tumor cell cycle. In the pathway of signal transmission of PI3K/AKT/PTEN/ mTOR, PTEN and roTOR are closely related through phosphorylation of AKT.
出处 《中国普通外科杂志》 CAS CSCD 2006年第3期181-184,共4页 China Journal of General Surgery
基金 国家高技术研究发展计划(863计划)资助项目(2002AA214061)
关键词 胆管癌细胞 抑癌基因 转染 QBC939细胞 细胞生长 Biliary Tract Carcinoma Cell Line Tumor Suppessor Gene Transfect
  • 相关文献

参考文献7

  • 1Downes CP,Bennett D,McConnachie G,et al.Antagonism of PI3-kinase-dependent signaling pathways by the tumour suppressor protein,PTEN[J].Biochem Soci Transactions,2001,29(6):846-890.
  • 2Huang S,Houghton PJ.Targeting mTOR signaling for cancer therpy[J].Cancer,2003,3(3):371-377.
  • 3Jianguo GU,Massahito TA,Kenneth MY et al.Shc and FAK differentially regulate edll motility and directionality modulated by PTEN[J].Cell Biol,1999,146(3):390-405.
  • 4Waite KA,Eng C.Protean PTEN:form and function[J].Am J Hum Genet,2002,70(4):829-844.
  • 5Shivapriya R,Noriaki N,William RS,et al.Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway[J].Cell Biol,1999,96(3):2110-2115.
  • 6汤聪,孙华文,李子禹,邹声泉.导入PTEN基因抑制胰腺癌细胞体外生长的研究[J].中华实验外科杂志,2003,20(3):242-243. 被引量:5
  • 7Guba M,Breitenbuch PV,Steinbauer M,et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor[J].Nature Med,2002,(6):128-135.

共引文献4

同被引文献58

  • 1崔平,普苹,赵晓霞,吴韬,杨世昆,胡筑培.胆系恶性肿瘤p16,PTEN和nm23基因的表达及其临床意义[J].中国普通外科杂志,2006,15(3):195-197. 被引量:4
  • 2刘民锋,罗剑,余险峰,唐启彬,陈勇军,邹声泉.PTEN和mTOR信号转导通路在胆管癌发展中作用的研究[J].中国普通外科杂志,2006,15(4):274-276. 被引量:13
  • 3Li J,Yen C,Liaw D,et al.PTEN,a putative protein tyrosine phosphatease gene mutated in human brain,breast,and prostate cancer[J].Science,1997,275 (5308):1943-1947.
  • 4Panigrahi AR,Pinder SE,Chan SY,et al.The role of PTEN and its signaling pathways,including AKT in breast cancer,an assessment of relationships with other prognostic factors and with outcome[J].J Pathol,2004,204 (1):93-100.
  • 5Tsttsui S,lnoue H,Yasuda K,et al.Inactivation of PTEN is associated with a low p27kipl protein expression in breast carcinoma[J].Cancer,2005,104 (10):2048-2053.
  • 6Chung JH,Eng L.Nuclear-cyoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10(PTEN)differentially regulates the cell cycle and apoptosis[J].Cancer Res,2005,65(18):8096 -8100.
  • 7He TC,Zhou S,Da Costo LT,et al.A simplified system for generating recombinant adenovirus[J].Proe Natl Acad Sci USA,1998,95(5):2509 -2514.
  • 8Khan SA, Thomas HC, Davidson BR, Taylor- Robinson SD. Cholangiocarcinoma. Lancet ,2005; 366:1303-1314 [PMID: 16214602 DOI: 10.1016/ S0140-6736 (05) 67530-7].
  • 9Shaib Y, E1-Serag HB The epidemiology of chol- angiocarcinoma. Semin Liver Dis ,2004; 24:115-125 [PMID: 15,192785 DOI: 10.1055/s-,2004-828889].
  • 10Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology ,2001; 33:1353-1357 [PM1D: 11391522 DOI: 10.1053/jhep.,2001.25087].

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部